Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT00089986
Registration number
NCT00089986
Ethics application status
Date submitted
18/08/2004
Date registered
23/08/2004
Date last updated
21/08/2017
Titles & IDs
Public title
GR270773 In The Treatment Of Suspected Or Confirmed Gram-Negative Severe Sepsis In Adults
Query!
Scientific title
A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults
Query!
Secondary ID [1]
0
0
EMD20001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Sepsis
0
0
Query!
Condition category
Condition code
Infection
0
0
0
0
Query!
Studies of infection and infectious agents
Query!
Inflammatory and Immune System
0
0
0
0
Query!
Other inflammatory or immune system disorders
Query!
Injuries and Accidents
0
0
0
0
Query!
Poisoning
Query!
Blood
0
0
0
0
Query!
Other blood disorders
Query!
Infection
0
0
0
0
Query!
Other infectious diseases
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Percentage of Participants With 28-Day All Cause Mortality
Query!
Assessment method [1]
0
0
Mortality was assessed by the number of participants who died between days 1 and 28. A summary of death details was given which included whether the participant died between days 1 and 28, whether the death was related sepsis, cause of death, the source of the information, and whether the cause of death was verified by a death record. Participants who had withdrawn from study and all study assessments and for whom survival at day 28 could not be confirmed was treated as deaths for the primary endpoint. The difference in all-cause 28-day mortality rates for each treatment group versus the placebo group in the ITT Population was calculated as placebo - treatment.
Query!
Timepoint [1]
0
0
Day 1 (post-infusion) up to Day 28 Follow-up
Query!
Secondary outcome [1]
0
0
Number of Participants With New Onset Organ Failure, Regardless of Cause, Occurring During the 28 Days Post Enrollment in an Organ Not in Failure at Enrolment
Query!
Assessment method [1]
0
0
The new onset organ failure was defined as first time each of the following criteria were met after start of study medication up to Day 28. Respiratory failure: defined by requiring mechanical ventilation not less than 24 hours due to surgery. Renal failure: defined by requiring the initiation of hemodialysis or hemofiltration. Coagulopathy: defined by disseminated intravascular coagulation (DIC) requiring transfusion with platelets or fresh frozen plasma or anticoagulant therapy. Cardiovascular failure: defined by sustained hypotension requiring vasopressor support of dopamine \>5 microgram per kilogram per minute (µg/kg/min), epinephrine, norepinephrine, phenylephrine or vasopressin at any dose if used to increase blood pressure for \>=6 continuous h. Analysis was done treating the death as a new onset organ failure (counted in both the numerator and denominator).
Query!
Timepoint [1]
0
0
Baseline (Day 1, pre-infusion) up to Day 28 Follow-up
Query!
Secondary outcome [2]
0
0
Number of Participants With New Onset Organ Failure of Respiratory Failure, Cardiovascular Failure, Renal Failure and Coagulopathy, Regardless of Cause, Occurring During the 28 Days Post Enrollment in an Organ Not in Failure at Enrollment
Query!
Assessment method [2]
0
0
Respiratory failure: defined by requiring mechanical ventilation not less than 24 hours due to surgery. Renal failure: defined by requiring the initiation of hemodialysis or hemofiltration. Coagulopathy: defined by disseminated intravascular coagulation (DIC) requiring transfusion with platelets or fresh frozen plasma or anticoagulant therapy. Cardiovascular failure: defined by sustained hypotension requiring vasopressor support of dopamine \>5 microgram per kilogram per minute (µg/kg/min), epinephrine, norepinephrine, phenylephrine or vasopressin at any dose if used to increase blood pressure for \>=6 continuous h. For each organ failure type and the number of new onset organ failures per participants for each organ failure type, the denominator only included participants who did not have that type of organ failure at Baseline. At Baseline a participant could enter the study with a type of organ failure, that type of failure was not reported as a new onset organ failure.
Query!
Timepoint [2]
0
0
Baseline (Day 1, pre-infusion) up to Day 28 Follow up
Query!
Secondary outcome [3]
0
0
Assessment of Safety/Tolerability by Determining the Number of Participants With Any Adverse Events (AE), Serious Adverse Events (SAE) and Fatal SAE
Query!
Assessment method [3]
0
0
An AE is defined as any untoward medical occurrence in a participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or is a congenital anomaly/birth defect, may jeopardize the participant or may require medical or surgical intervention to prevent one of the other outcomes listed in this definition or common toxicity criteria (CTC) grade 4 laboratory abnormalities of national cancer institute not associated with the underlying sepsis unless more severe than expected for the participants condition.
Query!
Timepoint [3]
0
0
Day 1 (pre-infusion) up to Day 28 Follow-up
Query!
Eligibility
Key inclusion criteria
Inclusion criteria:
* Receiving parenteral antibiotic therapy for a suspected or confirmed Gram-negative infection.
* Have at least one new hypoperfusion abnormality or at least one new onset organ failure resulting from the current septic episode.
* Must be available and able to receive the first dose of study medication no more than 12 hours after the confirmation of a new hypoperfusion abnormality or new onset organ failure and within 36 hours after the initiation of new parenteral antibacterial therapy for the suspected or confirmed Gram-negative infection believed to be responsible for this episode of sepsis.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
* Subject is unlikely to remain in hospital for a minimum of three days (72 hours) following enrollment.
* Subject has neutropenia (e.g., subject recently receiving cytotoxic chemotherapy with absolute neutrophil count <500/mcL or expected to decline to <500/mcL in the next 3 days).
* Subject has known active hemolytic disease, immune hemolytic anemias, hemoglobinopathies (sickle cell anemia and thalassemia major).
* Subject has a known bone marrow disorder of inadequate red cell production (eg, aplastic anemia, myelodysplasia).
* Subject is at increased risk of complications from GR270773-related hemolysis due to the inability to increase cardiac function sufficiently to meet the demands for oxygen delivery.
* Subject has a baseline hemoglobin (measured after adequate volume resuscitation) <9.0 g/dL (5.59 mmol/L).
* Subject is currently being treated with XIGRIS (Drotrecogin alfa (activated)) or its use is considered imminent (ie., a decision to treat with XIGRIS has been made).
* Subject has a history of allergic reaction to eggs (or egg products), soybeans, INTRALIPID, or any component of GR270773.
* Subject has been designated as 'not full support do not resuscitate' (DNR), or other equivalent status which prohibits the use of life supporting interventions (e.g., mechanical ventilation, dialysis/hemofiltration, or others) thereby limiting the treatment options available.
Note: Subjects with advanced directives prohibiting only chest compression (CPR) are eligible for the study.
* Subject has preexisting severe liver disease such as cirrhosis, primary biliary cirrhosis or known preexisting Child-Pugh class B or C liver dysfunction.
* Subject is moribund (a state in which death is perceived to be imminent) or has a life expectancy of less than 3 months due to an underlying disease.
* Subject is currently receiving one of the following prohibited concomitant medications; parenteral nutrition supplements containing lipid emulsions (e.g., INTRALIPID), amphotericin, liposomal amphotericin, or amphotericin B lipid complex.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
1/09/2004
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
15/04/2007
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1415
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
GSK Investigational Site - St Leonards
Query!
Recruitment hospital [2]
0
0
GSK Investigational Site - Footscray
Query!
Recruitment hospital [3]
0
0
GSK Investigational Site - Heidelberg
Query!
Recruitment hospital [4]
0
0
GSK Investigational Site - Nedlands
Query!
Recruitment hospital [5]
0
0
GSK Investigational Site - Fremantle
Query!
Recruitment postcode(s) [1]
0
0
2065 - St Leonards
Query!
Recruitment postcode(s) [2]
0
0
3011 - Footscray
Query!
Recruitment postcode(s) [3]
0
0
3084 - Heidelberg
Query!
Recruitment postcode(s) [4]
0
0
6009 - Nedlands
Query!
Recruitment postcode(s) [5]
0
0
6959 - Fremantle
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
Arkansas
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
California
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Colorado
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Connecticut
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Delaware
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
District of Columbia
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Florida
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Georgia
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Hawaii
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Illinois
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Indiana
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Iowa
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Kansas
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
Kentucky
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
Louisiana
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
Maryland
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Massachusetts
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Michigan
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Minnesota
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Mississippi
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Missouri
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Montana
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
New Jersey
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
New York
Query!
Country [27]
0
0
United States of America
Query!
State/province [27]
0
0
North Carolina
Query!
Country [28]
0
0
United States of America
Query!
State/province [28]
0
0
Ohio
Query!
Country [29]
0
0
United States of America
Query!
State/province [29]
0
0
Oklahoma
Query!
Country [30]
0
0
United States of America
Query!
State/province [30]
0
0
Oregon
Query!
Country [31]
0
0
United States of America
Query!
State/province [31]
0
0
Pennsylvania
Query!
Country [32]
0
0
United States of America
Query!
State/province [32]
0
0
Rhode Island
Query!
Country [33]
0
0
United States of America
Query!
State/province [33]
0
0
South Carolina
Query!
Country [34]
0
0
United States of America
Query!
State/province [34]
0
0
Tennessee
Query!
Country [35]
0
0
United States of America
Query!
State/province [35]
0
0
Texas
Query!
Country [36]
0
0
United States of America
Query!
State/province [36]
0
0
Utah
Query!
Country [37]
0
0
United States of America
Query!
State/province [37]
0
0
Vermont
Query!
Country [38]
0
0
United States of America
Query!
State/province [38]
0
0
Virginia
Query!
Country [39]
0
0
United States of America
Query!
State/province [39]
0
0
Washington
Query!
Country [40]
0
0
United States of America
Query!
State/province [40]
0
0
West Virginia
Query!
Country [41]
0
0
United States of America
Query!
State/province [41]
0
0
Wisconsin
Query!
Country [42]
0
0
Argentina
Query!
State/province [42]
0
0
Buenos Aires
Query!
Country [43]
0
0
Argentina
Query!
State/province [43]
0
0
Córdova
Query!
Country [44]
0
0
Argentina
Query!
State/province [44]
0
0
Ciudad de Buenos Aires
Query!
Country [45]
0
0
Argentina
Query!
State/province [45]
0
0
Moron-Provincia de Buenos Aires
Query!
Country [46]
0
0
Austria
Query!
State/province [46]
0
0
Innsbruck
Query!
Country [47]
0
0
Austria
Query!
State/province [47]
0
0
Vienna
Query!
Country [48]
0
0
Belgium
Query!
State/province [48]
0
0
Aalst
Query!
Country [49]
0
0
Belgium
Query!
State/province [49]
0
0
Brussel
Query!
Country [50]
0
0
Belgium
Query!
State/province [50]
0
0
Bruxelles
Query!
Country [51]
0
0
Belgium
Query!
State/province [51]
0
0
Genk
Query!
Country [52]
0
0
Belgium
Query!
State/province [52]
0
0
Gent
Query!
Country [53]
0
0
Belgium
Query!
State/province [53]
0
0
Leuven
Query!
Country [54]
0
0
Belgium
Query!
State/province [54]
0
0
Ottignies
Query!
Country [55]
0
0
Belgium
Query!
State/province [55]
0
0
Yvoir
Query!
Country [56]
0
0
Brazil
Query!
State/province [56]
0
0
Paraná
Query!
Country [57]
0
0
Brazil
Query!
State/province [57]
0
0
São Paulo
Query!
Country [58]
0
0
Canada
Query!
State/province [58]
0
0
Alberta
Query!
Country [59]
0
0
Canada
Query!
State/province [59]
0
0
British Columbia
Query!
Country [60]
0
0
Canada
Query!
State/province [60]
0
0
Manitoba
Query!
Country [61]
0
0
Canada
Query!
State/province [61]
0
0
New Brunswick
Query!
Country [62]
0
0
Canada
Query!
State/province [62]
0
0
Nova Scotia
Query!
Country [63]
0
0
Canada
Query!
State/province [63]
0
0
Ontario
Query!
Country [64]
0
0
Canada
Query!
State/province [64]
0
0
Quebec
Query!
Country [65]
0
0
Canada
Query!
State/province [65]
0
0
Saskatchewan
Query!
Country [66]
0
0
Chile
Query!
State/province [66]
0
0
Región Metro De Santiago
Query!
Country [67]
0
0
Czechia
Query!
State/province [67]
0
0
Brno
Query!
Country [68]
0
0
Czechia
Query!
State/province [68]
0
0
Ostrava - Poruba
Query!
Country [69]
0
0
Czechia
Query!
State/province [69]
0
0
Plzen
Query!
Country [70]
0
0
Czechia
Query!
State/province [70]
0
0
Praha 10
Query!
Country [71]
0
0
Czechia
Query!
State/province [71]
0
0
Praha 5
Query!
Country [72]
0
0
Estonia
Query!
State/province [72]
0
0
Tallinn
Query!
Country [73]
0
0
Estonia
Query!
State/province [73]
0
0
Tartu
Query!
Country [74]
0
0
Finland
Query!
State/province [74]
0
0
Helsinki
Query!
Country [75]
0
0
Finland
Query!
State/province [75]
0
0
Joensuu
Query!
Country [76]
0
0
Finland
Query!
State/province [76]
0
0
Jyvaskyla
Query!
Country [77]
0
0
Finland
Query!
State/province [77]
0
0
Kuopio
Query!
Country [78]
0
0
Finland
Query!
State/province [78]
0
0
Lappeenranta
Query!
Country [79]
0
0
Finland
Query!
State/province [79]
0
0
Mikkeli
Query!
Country [80]
0
0
Finland
Query!
State/province [80]
0
0
Oulu
Query!
Country [81]
0
0
Finland
Query!
State/province [81]
0
0
Seinajoki
Query!
Country [82]
0
0
Finland
Query!
State/province [82]
0
0
Tampere
Query!
Country [83]
0
0
France
Query!
State/province [83]
0
0
Angers
Query!
Country [84]
0
0
France
Query!
State/province [84]
0
0
Argenteuil
Query!
Country [85]
0
0
France
Query!
State/province [85]
0
0
Bourg en Bresse
Query!
Country [86]
0
0
France
Query!
State/province [86]
0
0
Caen
Query!
Country [87]
0
0
France
Query!
State/province [87]
0
0
Créteil
Query!
Country [88]
0
0
France
Query!
State/province [88]
0
0
Le Chesnay cedex
Query!
Country [89]
0
0
France
Query!
State/province [89]
0
0
Lille cedex
Query!
Country [90]
0
0
France
Query!
State/province [90]
0
0
Limoges cedex
Query!
Country [91]
0
0
France
Query!
State/province [91]
0
0
Lyon cedex
Query!
Country [92]
0
0
France
Query!
State/province [92]
0
0
Marseille cedex 20
Query!
Country [93]
0
0
France
Query!
State/province [93]
0
0
Marseille cedex 9
Query!
Country [94]
0
0
France
Query!
State/province [94]
0
0
Montauban
Query!
Country [95]
0
0
France
Query!
State/province [95]
0
0
Montpellier cedex 5
Query!
Country [96]
0
0
France
Query!
State/province [96]
0
0
Nîmes
Query!
Country [97]
0
0
France
Query!
State/province [97]
0
0
Paris cedex 10
Query!
Country [98]
0
0
France
Query!
State/province [98]
0
0
Paris cedex 14
Query!
Country [99]
0
0
France
Query!
State/province [99]
0
0
Paris
Query!
Country [100]
0
0
France
Query!
State/province [100]
0
0
Saint Michel
Query!
Country [101]
0
0
Germany
Query!
State/province [101]
0
0
Baden-Wuerttemberg
Query!
Country [102]
0
0
Germany
Query!
State/province [102]
0
0
Bayern
Query!
Country [103]
0
0
Germany
Query!
State/province [103]
0
0
Hessen
Query!
Country [104]
0
0
Germany
Query!
State/province [104]
0
0
Mecklenburg-Vorpommern
Query!
Country [105]
0
0
Germany
Query!
State/province [105]
0
0
Niedersachsen
Query!
Country [106]
0
0
Germany
Query!
State/province [106]
0
0
Nordrhein-Westfalen
Query!
Country [107]
0
0
Germany
Query!
State/province [107]
0
0
Rheinland-Pfalz
Query!
Country [108]
0
0
Germany
Query!
State/province [108]
0
0
Saarland
Query!
Country [109]
0
0
Germany
Query!
State/province [109]
0
0
Sachsen-Anhalt
Query!
Country [110]
0
0
Germany
Query!
State/province [110]
0
0
Sachsen
Query!
Country [111]
0
0
Germany
Query!
State/province [111]
0
0
Schleswig-Holstein
Query!
Country [112]
0
0
Germany
Query!
State/province [112]
0
0
Thueringen
Query!
Country [113]
0
0
Germany
Query!
State/province [113]
0
0
Berlin
Query!
Country [114]
0
0
Germany
Query!
State/province [114]
0
0
Bremen
Query!
Country [115]
0
0
Germany
Query!
State/province [115]
0
0
Hamburg
Query!
Country [116]
0
0
Greece
Query!
State/province [116]
0
0
Athens
Query!
Country [117]
0
0
Greece
Query!
State/province [117]
0
0
Haidari
Query!
Country [118]
0
0
Greece
Query!
State/province [118]
0
0
Kifisia
Query!
Country [119]
0
0
Greece
Query!
State/province [119]
0
0
Rio, Patras
Query!
Country [120]
0
0
Greece
Query!
State/province [120]
0
0
Thessaloniki
Query!
Country [121]
0
0
Hong Kong
Query!
State/province [121]
0
0
Kowloon
Query!
Country [122]
0
0
Hong Kong
Query!
State/province [122]
0
0
Pokfulam
Query!
Country [123]
0
0
Hong Kong
Query!
State/province [123]
0
0
Shatin
Query!
Country [124]
0
0
Hong Kong
Query!
State/province [124]
0
0
Tuen Mun, New Territories
Query!
Country [125]
0
0
Hungary
Query!
State/province [125]
0
0
Budapest
Query!
Country [126]
0
0
India
Query!
State/province [126]
0
0
Bangalore
Query!
Country [127]
0
0
India
Query!
State/province [127]
0
0
Chennai
Query!
Country [128]
0
0
India
Query!
State/province [128]
0
0
Mangalore
Query!
Country [129]
0
0
India
Query!
State/province [129]
0
0
Mumbai
Query!
Country [130]
0
0
India
Query!
State/province [130]
0
0
Pune
Query!
Country [131]
0
0
Israel
Query!
State/province [131]
0
0
Afula
Query!
Country [132]
0
0
Israel
Query!
State/province [132]
0
0
Beer-Sheva
Query!
Country [133]
0
0
Israel
Query!
State/province [133]
0
0
Haifa
Query!
Country [134]
0
0
Israel
Query!
State/province [134]
0
0
Kfar Saba
Query!
Country [135]
0
0
Israel
Query!
State/province [135]
0
0
Zrifin
Query!
Country [136]
0
0
Korea, Republic of
Query!
State/province [136]
0
0
Seoul
Query!
Country [137]
0
0
Latvia
Query!
State/province [137]
0
0
Riga
Query!
Country [138]
0
0
Malaysia
Query!
State/province [138]
0
0
Kuala Lumpur
Query!
Country [139]
0
0
Malaysia
Query!
State/province [139]
0
0
Kubang Kerian
Query!
Country [140]
0
0
Netherlands
Query!
State/province [140]
0
0
Amsterdam
Query!
Country [141]
0
0
Netherlands
Query!
State/province [141]
0
0
Apeldoorn
Query!
Country [142]
0
0
Netherlands
Query!
State/province [142]
0
0
Den Bosch
Query!
Country [143]
0
0
Netherlands
Query!
State/province [143]
0
0
EDE
Query!
Country [144]
0
0
Netherlands
Query!
State/province [144]
0
0
Leeuwarden
Query!
Country [145]
0
0
Netherlands
Query!
State/province [145]
0
0
Rotterdam
Query!
Country [146]
0
0
Netherlands
Query!
State/province [146]
0
0
Utrecht
Query!
Country [147]
0
0
New Zealand
Query!
State/province [147]
0
0
Auckland
Query!
Country [148]
0
0
New Zealand
Query!
State/province [148]
0
0
Christchurch
Query!
Country [149]
0
0
New Zealand
Query!
State/province [149]
0
0
Tauranga
Query!
Country [150]
0
0
Portugal
Query!
State/province [150]
0
0
Almada
Query!
Country [151]
0
0
Portugal
Query!
State/province [151]
0
0
Amadora
Query!
Country [152]
0
0
Portugal
Query!
State/province [152]
0
0
Lisboa
Query!
Country [153]
0
0
Puerto Rico
Query!
State/province [153]
0
0
San Juan
Query!
Country [154]
0
0
Romania
Query!
State/province [154]
0
0
Bucharest
Query!
Country [155]
0
0
Romania
Query!
State/province [155]
0
0
Iasi
Query!
Country [156]
0
0
Russian Federation
Query!
State/province [156]
0
0
Barnaul
Query!
Country [157]
0
0
Russian Federation
Query!
State/province [157]
0
0
Ekaterinburg
Query!
Country [158]
0
0
Russian Federation
Query!
State/province [158]
0
0
Krasnodar
Query!
Country [159]
0
0
Russian Federation
Query!
State/province [159]
0
0
Moscow
Query!
Country [160]
0
0
Russian Federation
Query!
State/province [160]
0
0
Perm
Query!
Country [161]
0
0
Russian Federation
Query!
State/province [161]
0
0
Smolensk
Query!
Country [162]
0
0
Russian Federation
Query!
State/province [162]
0
0
St. Petersburgh
Query!
Country [163]
0
0
Russian Federation
Query!
State/province [163]
0
0
Tomsk
Query!
Country [164]
0
0
Slovenia
Query!
State/province [164]
0
0
Celje
Query!
Country [165]
0
0
Slovenia
Query!
State/province [165]
0
0
Ljubljana
Query!
Country [166]
0
0
Slovenia
Query!
State/province [166]
0
0
Maribor
Query!
Country [167]
0
0
Slovenia
Query!
State/province [167]
0
0
Novo Mesto
Query!
Country [168]
0
0
Slovenia
Query!
State/province [168]
0
0
Slovenj Gradec
Query!
Country [169]
0
0
Slovenia
Query!
State/province [169]
0
0
Šempeter pri Novi Gorici
Query!
Country [170]
0
0
South Africa
Query!
State/province [170]
0
0
Gauteng
Query!
Country [171]
0
0
South Africa
Query!
State/province [171]
0
0
Auckland Park, Johannesburg
Query!
Country [172]
0
0
South Africa
Query!
State/province [172]
0
0
Bloemfontein
Query!
Country [173]
0
0
South Africa
Query!
State/province [173]
0
0
Cape Town
Query!
Country [174]
0
0
South Africa
Query!
State/province [174]
0
0
George
Query!
Country [175]
0
0
South Africa
Query!
State/province [175]
0
0
PO Medunsa
Query!
Country [176]
0
0
Spain
Query!
State/province [176]
0
0
Badalona
Query!
Country [177]
0
0
Spain
Query!
State/province [177]
0
0
Barcelona
Query!
Country [178]
0
0
Spain
Query!
State/province [178]
0
0
Getafe
Query!
Country [179]
0
0
Spain
Query!
State/province [179]
0
0
La Coruña
Query!
Country [180]
0
0
Spain
Query!
State/province [180]
0
0
Madrid
Query!
Country [181]
0
0
Spain
Query!
State/province [181]
0
0
Palma de Mallorca
Query!
Country [182]
0
0
Spain
Query!
State/province [182]
0
0
Sevilla
Query!
Country [183]
0
0
Spain
Query!
State/province [183]
0
0
Tarrasa
Query!
Country [184]
0
0
Spain
Query!
State/province [184]
0
0
Terrassa
Query!
Country [185]
0
0
Spain
Query!
State/province [185]
0
0
Valencia
Query!
Country [186]
0
0
Sweden
Query!
State/province [186]
0
0
Göteborg
Query!
Country [187]
0
0
Sweden
Query!
State/province [187]
0
0
Lund
Query!
Country [188]
0
0
Sweden
Query!
State/province [188]
0
0
Stockholm
Query!
Country [189]
0
0
Taiwan
Query!
State/province [189]
0
0
Kaohsiung
Query!
Country [190]
0
0
Taiwan
Query!
State/province [190]
0
0
Taichung
Query!
Country [191]
0
0
Taiwan
Query!
State/province [191]
0
0
Taipei
Query!
Country [192]
0
0
Taiwan
Query!
State/province [192]
0
0
Tau-Yuan County
Query!
Country [193]
0
0
Thailand
Query!
State/province [193]
0
0
Bangkok
Query!
Country [194]
0
0
Thailand
Query!
State/province [194]
0
0
Chiangmai
Query!
Country [195]
0
0
United Kingdom
Query!
State/province [195]
0
0
Aberdeenshire
Query!
Country [196]
0
0
United Kingdom
Query!
State/province [196]
0
0
Berkshire
Query!
Country [197]
0
0
United Kingdom
Query!
State/province [197]
0
0
Lanarkshire
Query!
Country [198]
0
0
United Kingdom
Query!
State/province [198]
0
0
Lancashire
Query!
Country [199]
0
0
United Kingdom
Query!
State/province [199]
0
0
Merseyside
Query!
Country [200]
0
0
United Kingdom
Query!
State/province [200]
0
0
Oxfordshire
Query!
Country [201]
0
0
United Kingdom
Query!
State/province [201]
0
0
Somerset
Query!
Country [202]
0
0
United Kingdom
Query!
State/province [202]
0
0
West Lothian
Query!
Country [203]
0
0
United Kingdom
Query!
State/province [203]
0
0
Leeds
Query!
Country [204]
0
0
United Kingdom
Query!
State/province [204]
0
0
Sheffield
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
GlaxoSmithKline
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
The primary objective is to estimate the size of the GR270773 treatment effect on 28-day all-cause mortality for two doses of GR270773 versus placebo in adult subjects with suspected or confirmed Gram-negative severe sepsis. GR270773 will be administered as a three-day continuous intravenous infusion.
Query!
Trial website
https://clinicaltrials.gov/study/NCT00089986
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
GSK Clinical Trials
Query!
Address
0
0
GlaxoSmithKline
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
No documents have been uploaded by study researchers.
Results are available at
https://clinicaltrials.gov/study/NCT00089986
Download to PDF